Platelia SARS-CoV-2 Total Ab Assay - Detection of IgM, IgA, and IgG in One Test

As COVID-19 continues to impact countries worldwide, accurate screening is needed to establish serological status of different populations. Bio-Rad now offers the Platelia SARS-CoV-2 Total Ab assay, for the detection of total anti-nucleocapsid antibodies (IgM, IgA, IgG) to SARS-CoV-2. In one test, the assay helps identify the immune response to coronavirus SARS-CoV-2, the virus associated with COVID-19. The Platelia SARS-CoV-2 Total Ab assay reliably detects patients that have been exposed to SARS-CoV-2. The assay achieved 98% sensitivity overall, with 92% sensitivity for patients tested ≤ 8 days after onset of symptoms and 100% sensitivity for patients tested > 8 days after onset of symptoms. The assay showed >99% specificity for specimens from 500 blood donors and 100 hospitalized patients negative for SARS-CoV-2. A total of
600 specimens were tested.